

Introduction

- Cystic fibrosis is an autosomal recessive genetic disorder that affects the lungs, the pancreas, the liver and the intestine.
- The pharmacotherapy contributes to a better quality of life, reduced hospitalizations and prolonged survival.

Objectives

 The aim of this study was to review the literature on the impact and the role of pharmacists in cystic fibrosis.

Methods

A Web portal about the evidences of the impact and the role of pharmacists in specific diseases, programs of care or pharmaceutical activities was developed.

http://impactpharmacie.org

- A literature search on Pubmed® was conducted: pharmacist OR clinical pharmacy OR pharmaceutical care AND cystic fibrosis.
- French and English articles about the role and the impact of pharmacists in cystic fibrosis from 1990-2013 were included.
- For each article we included:
- . all key indicators that document the the role of pharmacists with only quantitative or qualitative metrics.
- . all key indicators that document the impact of pharmacist with statistical analysis
- . all relevant pharmaceutical activities in that context

Discussion/Conclusion

- There are limited data published about the role of pharmacists in cystic fibrosis.
- While it seems relevant to support such clinical implication, pharmacists involved in that program of care should better document and evaluate their impact.

Impact and role of pharmacists in cystic fibrosis

Guérin A¹, Lebel D¹, Bussières JF^{1,2}

¹Pharmacy Department, Pharmacy Practice Research Unit, CHU Sainte-Justine, ²Faculty of Pharmacy, Université de Montréal, Canada

Re . . .

		Kev indicators that docum	ent the impact of p	harmacists wit	h statistical	
Literature search		Key indicators that document the impact of pharmacists with statistical analysis				
Four relevant articles included in our analysis		Categories of key indicators				
		(Number of keys indicators)	Number of articles	Number of articles		
		Costs (4)	1	-	-	
		Adverse effect (no data)		-	-	
		Errors (no data)		-	-	
24 key indicators that document the role of pharmacists with only quantitative or qualitative metrics Nine key indicators that document the impact of pharmacist with statistical analysis Six pharmaceutical activities		Morbidity (2)	1	1	-	
		Mortality (no data)		-	-	
		Adherence (no data)		-	-	
Six pharmaceutical activities		Satisfaction (no data)		-	-	
Key indicators (quantitative	or qualitative)	Others (3) Legend Others Positive impact	Neutral impact	ative impact		
Settings	or qualitative) Number of articles	Legend Order Positive impact				
Settings lospital		Legend Positive impact		« Others » ind		
Settings Iospital Iospital for children		Legend Positive impact		 Others > ind Mean levels 	s per patient	
Settings Iospital Iospital for children Iniversity hospital		Legend Positive impact in the second	dicators Morbidity » indicator 1/ Schedule for the evaluar	 <i>«</i> Others » ind <i>•</i> Mean levels <i>•</i> Mean numb <i>i</i> achieve pha 	s per patient per of days to armacokinetic	
Settings lospital lospital for children Iniversity hospital Patient care wards		Legend Positive impact in the second	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 <i>«</i> Others » ind <i>Mean levels</i> <i>Mean numb</i> <i>Mean numb</i> <i>achieve pha</i> <i>and pharma</i> 	s per patient per of days to	
Settings lospital lospital for children Iniversity hospital Patient care wards	Number of articles 1 2 1	Legend Positive impact in the second	dicators Morbidity » indicator 1/ Schedule for the evaluar	 A Mean levels Mean numb achieve pha and pharma goal Number of o achieved pharma 	s per patient ber of days to armacokinetic acodynamics courses that harmacokinetic	
Settings lospital lospital for children University hospital Patient care wards Cystic fibrosis center	Number of articles 1 2 1 3	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 A Second Structure A Mean levels Mean number of a achieved pharma Mumber of a achieved pharma 	s per patient ber of days to armacokinetic acodynamics	
ettings ospital ospital for children niversity hospital atient care wards systic fibrosis center	Number of articles 1 2 1	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 A Mean levels Mean numb achieve pha and pharma goal Number of o achieved pharma 	s per patient ber of days to armacokinetic acodynamics courses that harmacokinetic	
ettings lospital lospital for children niversity hospital atient care wards cystic fibrosis center Categories of key indicators Number of keys indicators)	Number of articles 1 2 1 3	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 A Second Structure A Mean levels Mean number of a achieved pharma Mumber of a achieved pharma 	s per patient ber of days to armacokinetic acodynamics courses that harmacokinetic	
Settings Iospital Iospital for children Iniversity hospital Patient care wards Cystic fibrosis center Categories of key indicators Number of keys indicators) Costs (4)	Number of articles 1 2 1 3	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 A Second Structure A Mean levels Mean number of a achieved pharma Mumber of a achieved pharma 	<text></text>	
ettings ospital ospital for children niversity hospital atient care wards ystic fibrosis center categories of key indicators Number of keys indicators) costs (4) dverse effects	Number of articles 1 2 1 3 Number of articles 2	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1/ Schedule for the evaluat of individual quality of lif	 A (* Others » ind A Mean levels A Mean numbrait A Matha numbrait A Matha numbrait A Matha numbrait A Matha n	s per patient ber of days to armacokinetic codynamics	
Settings lospital lospital for children Iniversity hospital Patient care wards	Number of articles 1 2 1 3 Number of articles 2	Legend Positive impact () Positive impact ()	dicators Morbidity » indicator 1. Schedule for the evaluar of individual quality of lif direct weighting	 A Second and pharma and pharma	s per patient ber of days to armacokinetic codynamics	
ettings lospital lospital for children Iniversity hospital Patient care wards Cystic fibrosis center Categories of key indicators Number of keys indicators) Costs (4) Adverse effects Errors (1)	Number of articles 1 2 1 3 Number of articles 2 No data 1	Legend Positive impact () Positive key ind Positive key ind () () () () () () () () () ()	dicators Morbidity » indicator 1. Schedule for the evaluar of individual quality of lif direct weighting	 A Second and pharma and pharma	s per patient er of days to armacokinetic acodynamics	

<u>sults</u>							
Literature search		Key indicators that document the impact of pharmacists with statistical analysis					
Four relevant articles included in our analysis		Categories of key indicators	••				
		(Number of keys indicators)	Number of articles	Number of articles			
		Costs (4)	1	-	-		
		Adverse effect (no data)		_			
24 key indicators that decument the role of phormosists with		Auverse enect (no data)					
		Errors (no data)	-	-	-		
24 key indicators that document the role of pharmacists with only quantitative or qualitative metrics Nine key indicators that document the impact of pharmacist with statistical analysis		Morbidity (2)	1	1			
		Mortality (no data)		_	-		
		Adherence (no data)	_	_	_		
Six pharmaceutical activities		Satisfaction (no data)		_			
		Others (3)					
Settings Hospital	Number of articles1	Positive key indi	cators	« Others » ind	icator 3/3		
lospital for children	2		lorbidity » indicator 1/	 Mean levels 	• •		
Iniversity hospital	1		Schedule for the evaluat				
Patient care wards Cystic fibrosis center	3	Drug level costs	f individual quality of lif	e- and pharmad			
Categories of key indicators	Number of articles	 Dosing adjustement costs Lenght of stay cost Total costs 	irect weighting	goal Number of car achieved pharmad and pharmad goal 	armacokinetic		
Number of keys indicators)							
Costs (4)							
dverse effects	2						
rrors (1)	2 No data			Pharmaco kinetics			
	۷				on		
	۷		Mec	kinetics consultation (n=2)	on Drug t		
lorbidity	No data	Pharmaceutical activities	Mec rour (n-	kinetics consultatio (n=2)	on Drug t evalu		
lorbidity lortality	No data 1 No data No data	Pharmaceutical activities (n articles)		kinetics consultatio (n=2)	on Drug f evalu		
Morbidity Mortality Adherence Satisfaction (2) Others (7)	 No data No data No data No data No data 		rou	kinetics consultatio (n=2)	on Drug th evalua (n=		

An article can have several indicators.

An indicator may be present in one or more articles.







Conflict of interest: none